Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Potential role of sorafenib as neoadjuvant therapy in unresectable papillary thyroid cancer

Published:2018-05-07 Issue: Volume: Page:
ISSN:2359-3997
Container-title:Archives of Endocrinology and Metabolism
language:en
Short-container-title:

Author:

Danilovic Debora L. S.,Castro Gilberto,Roitberg Felipe S. R.,Vanderlei Felipe A. B.,Bonani Fernanda A.,Freitas Ricardo M. C.,Coura-Filho George B.,Camargo Rosalinda Y.,Kulcsar Marco A.,Marui Suemi,Hoff Ana O.

Publisher

Archives of Endocrinology and Metabolism

Subject

Endocrinology, Diabetes and Metabolism

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial;Journal of the Endocrine Society;2024-07-12

2. Targeted Therapy in Thyroid Cancer;Indian Journal of Endocrine Surgery and Research;2024-06-17

3. Donafenib as neoadjuvant therapy in locally advanced thyroid cancer: protocol for the DONATHYCA phase II prospective single-arm trial in China;BMJ Open;2024-05

4. Neoadjuvant therapy to improve resectability of advanced thyroid cancer: A real‐world experience;Head & Neck;2024-03-15

5. The Efficacy and Safety of Surufatinib Combined with Anti PD-1 Antibody Toripalimab in Neoadjuvant Treatment of Locally Advanced Differentiated Thyroid Cancer: A Phase II Study;Annals of Surgical Oncology;2023-08-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP